Unity Biotechnology Q1 net loss $5.8M, cash $38.3M; ASPIRE DME study on track

Unity Biotechnology, Inc.

2024-Q1 EPS reported -$0.34

Net loss $5.8M for Q1 2024 vs $5.3M in Q1 2023; cash & securities $38.3M as of Mar 31, 2024.
R&D expenses decreased to $3.7M from $5.8M due to completion of prior studies; focus on ASPIRE.
Phase 2b ASPIRE study for UBX1325 in DME upsized to 50 patients, extended to 36 weeks; 24-week data expected Q1 2025, 36-week data Q2 2025.
Cash runway sufficient into Q3 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Unity Biotechnology, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-059749

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.